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Abstract 
Background: The potential benefits of cannabis and its major non-intoxicating component 
cannabidiol (CBD) are attracting attention, including as a potential treatment in 
neurodevelopmental disorders such as autism spectrum disorder (ASD). However, the neural 
action of CBD, and its relevance to ASD, remains unclear. We and others have previously 
shown that response to drug challenge can be measured using functional magnetic resonance 
imaging (fMRI); but that pharmacological responsivity is atypical in ASD. 
Aims: Therefore, we hypothesized that there would be a (different) fMRI response to CBD in 
ASD.  
Methods: To test this, task-free fMRI was acquired in 34 healthy men (half with ASD) following 
oral administration of 600 mg CBD or matched placebo (random order; double blind 
administration). The ‘fractional Amplitude of Low Frequency Fluctuations’ (fALFF) was 
measured across whole brain; and, where CBD significantly altered fALFF, we tested if 
functional connectivity (FC) of those regions was also affected by CBD.  
Results: CBD significantly increased fALFF in the cerebellar vermis and the right fusiform 
gyrus. However, post-hoc within-group analyses revealed that this effect was primarily driven 
by the ASD group, with no significant change in controls. Within the ASD group only, CBD also 
significantly altered vermal FC with several of its subcortical (striatal) and cortical targets; but 
did not affect fusiform FC with other regions in either group.  
Conclusion: Our results suggest that, especially in ASD, CBD alters regional fALFF and FC 
in/between regions consistently implicated in ASD. Future studies should examine if this 
affects the complex behaviours these regions modulate.  
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Introduction 
 
Autism spectrum disorder (ASD) is a common (Baio et al., 2018) and complex 
neurodevelopmental psychiatric condition, which shortens life expectancy by up to 20 years 
(Hirvikoski et al., 2016). Moreover, 70% of autistic individuals are estimated to have co-
occurring conditions, e.g. epilepsy (Tuchman and Rapin, 2002), mood and anxiety disorders 
(Joshi et al., 2013). However, there are no effective pharmacological treatments for the core 
symptoms of ASD, and individuals often respond poorly to conventional treatments of 
complicating mental or physical illnesses. Alternative treatment approaches, such as cannabis 
and its major non-intoxicating component cannabidiol (CBD) (Fetterman and Turner, 1972), 
are therefore increasingly explored.   
 
There is accumulating evidence for the efficacy of CBD in several conditions, such as spasticity 
in multiple sclerosis (Zajicek et al., 2003) and schizophrenia (Bhattacharyya et al., 2018); and 
in conditions associated with ASD, including social phobia (Bergamaschi et al., 2011) and 
epilepsy (Devinsky et al., 2016). Moreover, there are preliminary reports of beneficial effects 
of medical marihuana in idiopathic ASD itself (Campbell et al., 2017; Aran et al., 2018). For 
instance, a recent study has demonstrated that CBD-rich cannabis reduced behavioural 
outbreaks in children with ASD and severe behavioural problems (Aran et al., 2018). Thus, a 
role for CBD in ASD management warrants further attention. Consequently, there are now at 
least two clinical trials of CBD in ASD (clinicaltrials.gov; identifiers NCT03900923 and 
NCT02956226). Thus, a role for CBD in ASD management warrants further attention. 
However, we still have only limited understanding of how the typical human brain, let alone 
the autistic brain, responds to CBD. Hence, a fuller understanding of the mechanism of action 
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of CBD on brain, and its relevance to ASD, is desirable before investing in large scale clinical 
trials.  
 
Brain responsivity to pharmacological challenges can, for example, be measured using 
functional magnetic resonance imaging (fMRI) (Bhattacharyya et al., 2015; Fusar-Poli et al., 
2010; Grimm et al., 2018). Evidence that such approaches are sensitive to CBD effects comes 
from studies in both neurotypicals and individuals with schizophrenia. For instance, CBD 
reduced fronto-striatal – and decreased mediotemporal-prefrontal – FC during a visual 
oddball salience task; and enhanced salience processing (Bhattacharyya et al., 2015). CBD also 
disrupted prefrontal-subcortical connectivity during the processing of fearful faces (Fusar-Poli 
et al., 2010), and increased fronto-striatal activity at rest (Grimm et al., 2018). In 
schizophrenia, an acute dose of CBD was reported to ‘normalize’ brain activity in regions 
during a verbal learning paradigm (Bhattacharyya et al., 2018). Similarly, fMRI has been used 
as a marker for other drug challenges in ASD, such as riluzole, propranolol or oxytocin 
(Narayanan et al., 2010; Gordon et al., 2016; Ajram et al., 2017). However, the vast majority 
of these previous studies acquired fMRI during cognitive tasks. 
 
Although this approach provides valuable task-specific information, it constrains the analysis 
of drug response to task-relevant brain regions (and so misses the potential impact of a drug 
on whole brain function). Moreover, in a condition like ASD, where the performance of such 
higher cognitive tasks can be compromised (e.g. (Ashwin et al., 2007; Daly et al., 2012)), 
disentangling the effects of a drug from the demands of the task can be challenging. Thus, to 
examine whole-brain impact of CBD in individuals with and without ASD, we elected to use a 
resting state design. 
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Therefore, in this randomized, placebo-controlled, double-blind, cross-over study we adopted 
a whole-brain, task-free (resting state) design to compare brain response to CBD in individuals 
with and without ASD. We used resting state fMRI to examine the fractional amplitude of low 
frequency fluctuations (fALFF) (0.01-0.1Hz) as a measure of spontaneous regional brain 
activity (Cordes et al., 2001). These low frequency oscillations are thought to subsequently 
support the synchronisation of activity between spatially distinct regions (i.e. functional 
connectivity, FC) (Friston et al., 1993). Therefore, in regions where a significant shift in fALFF 
was observed, we also conducted a secondary seed-based analysis of FC of that region with 
the rest of the brain. Data were acquired following a single oral dose of 600 mg CBD or a 
matched placebo (at least 13 days apart). We predicted that CBD would alter regional fALFF; 
and subsequently shift FC of those regions which responded. Moreover, based on our 
previous findings that the autistic brain responds atypically to pharmacological challenge 
(Ajram et al., 2017), we expected that responsivity to CBD would be different in autistic 
compared to neurotypical individuals. 
 
Materials and Methods 
Procedure 
This research was conducted in accordance with the Declaration of Helsinki, at the Institute 
of Psychiatry, Psychology, and Neuroscience (IoPPN) at De Crespigny Park, sE5 8AF, London, 
UK (August 2016 to February 2017). Ethical approval for this study was provided by the King’s 
College London Research Ethics Committee, study reference HR15/162744. All participants 
provided written informed consent. Every participant took part in all aspects of this case-
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control observational study. The Medicines and Health Research Authority (MHRA) in the UK 
confirmed that our study design is not a Clinical Trial; however, in the interests of 
transparency this observational study was registered on clinicaltrials.gov (identifier: 
NCT03537950, entry name: HR15-162744). 
 
This was a placebo-controlled, randomised, double-blind, repeated-measures, cross-over 
study conducted as part of a larger investigation into the role of phytocannabinoids in ASD. 
Drugs were allocated in a pseudo-randomised order, so that each participant received each 
drug (PLC, CBD) once, and that approximately half of our participants attended a placebo visit 
before CBD; and half received CBD before placebo. This randomisation was implemented by 
Prof McAlonan using https://www.random.org/. Participants and those assessing outcomes 
were blinded to the assignment. Participants attended for two visits. To allow for drug wash-
out, visits were separated each by a minimum of 13 days, with all attempts made to keep 
between-visit time consistent across all visits and participants. Moreover, time of data 
acquisition from both groups was largely overlapping. On each visit, urine samples were taken 
to screen for illicit substances (a full list is included below). Subsequently, participants 
underwent a brief health check and received a liquid oral dose of the pharmacological probe 
(600 mg of CBD or a matched placebo, both provided by GW Research Ltd, Cambridge, UK). 
The dose of 600 mg of CBD has previously been demonstrated to be sufficient to elicit an 
effect on brain in adults, e.g. (Bhattacharyya et al., 2015); while being very well tolerated (GW 
Pharmaceuticals Investigator Brochure 2015). After a second brief health check to test for 
potential acute adverse reactions/side effects, participants underwent scanning timed to 
coincide with peak plasma (2 h) concentration. Following the scan, participants received a 
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third health check to ensure they had experienced no ill-effects and were fit to leave the 
department.  
 
Participants 
Potential participants were excluded if they had a comorbid major psychiatric or medical 
disorder affecting brain development (e.g. schizophrenia or epilepsy), a history of head/brain 
injury, a genetic disorder associated with ASD (e.g. tuberous sclerosis or Fragile X syndrome), 
an IQ below 70, or were reliant on receiving regular medication known to modulate directly 
the neurotransmitters glutamate and GABA. However, we included participants on other 
medications which are frequently prescribed in this condition. Thus, one autistic participant 
received a single dose of Ritalin on the morning of each test day, and another autistic 
participant took a single dose of sertraline on the morning of each visit. All participants were 
asked to abstain from using cannabis and/or other illicit substances in the month prior to 
scanning, and from drinking alcohol on the day prior to testing. Moreover, data from 
individuals who screened positive for illicit substances in the urine drug screening were 
excluded. Thus, we retained data from 34 subjects (17 neurotypicals, 17 ASD) (see Table 1 for 
demographics). All participants in the ASD group had a clinical diagnosis of ASD made 
according to ICD10 research criteria, supported by the use of standardised research 
diagnostic instruments (Autism Diagnostic Observation Schedule, ADOS; and Autism 
Diagnostic Interview-Revised, ADI-R) (World Health Organisation, 2016; Lord et al., 1994; 
Lord, 1989).  
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Imaging data acquisition 
We acquired all imaging data on a 3T GE Excite II magnetic resonance imaging (MRI) scanner 
(GE Medical Systems, Milwaukee, WI, USA). Our scanning protocol included a structural MRI 
scan acquired using a 3D inversion recovery prepared fast spoiled gradient recalled (IR-FSPGR) 
sequence (slice thickness = 1.1 mm, spatial positions = 124, flip angle = 20, field of view (FoV) 
= 280 mm, echo time (TE) = 2.844 ms, repetition time (TR) = 7.068 ms, inversion time (TI) = 
450 ms, matrix = 256x256). This structural MRI scan was used for co-registration of the 
functional volumes. The scanning protocol further included a resting state MRI scan. This scan 
was acquired using an echo-planar imaging (EPI) sequence (slice thickness = 3 mm, slice gap 
= 3.3 mm, flip angle = 75, FoV = 240 mm, TE = 30 ms, TR = 2000 ms, TI = 0 ms). We collected 
data for 256 time points, i.e. the resting state scan lasted 512 s. 
 
Urine test 
We performed liquid chromatography-mass spectrometry (LC-MS) analysis on urine samples 
provided by each participant before the drug administration to test for the presence or 
absence of illicit substances that could confound potential effects of the pharmacological 
probes tested here. Participants showing positive results for any of the drugs tested, including 
Amphetamines (Amphetamine, Methamphetamine, MDMA/Ecstasy), Benzodiazepines, 
Cannabis, Cocaine (as benzoylecgonine), Methadone and its metabolite EDDP, and Opioids 
(6-Monoacetylmorphine, Morphine, Codeine, Dihydrocodeine), were excluded from the 
analysis. This resulted in the exclusion of four subjects (two neurotypicals, two ASD) from the 
original sample.  
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Data processing 
Structural data processing 
T1-weighted structural MRI volumes were inspected manually to ensure adequate data 
quality and signal-to-noise ratio. Next, structural volumes were normalized to Montreal 
Neurological Institute (MNI) space, and segmented into grey matter (GM), white matter 
(WM), and cerebrospinal fluid (CSF), to enable the removal of WM and CSF confounds using 
linear regression.  
 
Resting state data processing 
We processed our resting state data using in-house software, CONN v.17c (Whitfield-Gabrieli 
and Nieto-Castanon, 2012), DPABI v.2.1 (Yan et al., 2016), and MATLAB R2017a (The 
MathWorks, Inc., MA, USREF). To ensure adequate data quality, all data were inspected 
manually for artefacts such as blurring, distortions, ghosting, or warping. The first 5 functional 
volumes were discarded to allow for magnetization equilibrium.  
 
Using CONN, all remaining functional volumes were slice-time corrected (sinc-interpolation), 
realigned (within runs to first volume, then all volumes to first volume of first run), and 
normalized to MNI space, using the segmented (into GM, WM, and CSF) structural scans.  
 
Head motion is thought to affect measures of FC (Power et al., 2012), and could potentially 
affect fALFF. To account for head motion, for each subject and run, we computed the frame-
to-frame displacement (> 1.5 mm/° translation/rotation classified as motion outlier). 
Following previous studies (e.g. (Gordon et al., 2016)), we used a joint threshold, where 
subjects with movement in any dimension ≥ 2 mm and/or ≥ 15% of volumes identified as 
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motion outliers were excluded from the analysis. This resulted in the exclusion of four runs 
from four subjects (all ASD). Thus, we retained a sample of 17 neurotypicals and 13 individuals 
with ASD.  
 
fALFF data processing 
Using DPABI, the functional data were detrended (linear trend removal), and denoised (WM, 
CSF, and movement confounds removed through linear regression). Subsequently, the time 
series of each voxel was transformed into the frequency domain using a Fast Fourier 
transform (as described in (Song et al., 2011)). Next, we obtained the power spectrum and 
calculated the square root (amplitude) at each frequency of the power spectrum. The sum of 
amplitudes across the low frequency spectrum (0.01 < f < 0.1 Hz) was divided by that across 
the entire frequency range (0 < f < 0.25 Hz). Individual fALFF maps were then standardized (Z-
value; subtraction of global mean, and division by standard deviation) within a brain mask 
(average GM mask across all subjects) and smoothed (using a Gaussian filter with a 6 mm full 
width at half maximum (FWHM) kernel). In summary, our analysis of low frequency 
fluctuations proceeded on a voxel by voxel basis. 
 
FC data processing 
Using CONN, data were smoothed (using a 6 mm FWHM Gaussian kernel), detrended (linear 
trend removal), denoised (WM, CSF, realignment, and movement confounds removed 
through linear regression), and band-pass filtered.  
In contrast to our fALFF analysis, our analysis of interregional FC used the average activity 
within predefined regions of interest (ROIs), based on standard whole brain atlases provided 
by CONN). These FC measures reflect the correlations between pairs of discrete ROIs. We 
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tested for experimental effects on the FC between key regions – identified in the voxel-based 
analysis of low frequency fluctuations, using standard analysis of variance. 
 
 
 
 
 
Statistical analysis 
Demographic measures (age, IQ) were compared using a one-way ANOVA (significance level 
p < 0.05).  
 
We first compared baseline levels of fALFF within GM regions between groups using a two-
sample t-test with non-parametric inference (TFCE, pFWE < 0.05) with 5000 permutations.  
 
To test our primary hypothesis that CBD modulates fALFF within GM regions, we used a 2 x 2 
factorial design with group (neurotypicals, ASD) as between-subject factor, drug (PLC, CBD) 
as within-subject factor, and regional fALFF as the dependent variable. We used non-
parametric inference at a familywise error rate (FWE) q = 0.05 (5000 permutations) and 
Threshold Free Cluster Enhancement (TFCE). As outlined in the introduction, we also wanted 
to examine the consistency of this response across groups and to establish if a CBD effect was 
indeed present within each group. Hence, in regions where we discovered a significant effect 
of drug, we performed planned post-hoc tests of these drug effects within each group 
separately using non-parametric inference (TFCE, pFWE < 0.05) with 5000 permutations. 
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Our secondary hypothesis was that CBD modulates FC between the regions identified in our 
fALFF analysis and the rest of the brain separately in ASD and neurotypicals. To this aim we 
conducted planned post-hoc tests within each group to examine potential effects of CBD on 
FC of those regions with the rest of the brain, using a seed-based repeated-measures design 
(connection-level threshold: puncorr = .05; seed-level threshold, and False Discovery Rate (FDR): 
pFDR = .05).  
 
All analyses were performed using SPSS 24.00 software (SPSS, Chicago, IL, USA), DPABI v.2.1 
(Yan et al., 2016) and Conn v.17c (Whitfield-Gabrieli and Nieto-Castanon, 2012).  
 
Results 
Demographics 
Groups did not differ significantly in age (F(1) = 0.634, p = .443) or in full-scale IQ (F(1) = 3.230, 
p = .083). We observed no subjective or objective ill-effects/harm following administration of 
the study drug in any of our participants. Table 1  
 
Table 1 Participant demographics for all subjects including standard deviations. Abbreviations: autism spectrum 
disorder, ASD; female, F; F statistic and degrees of freedom, F(dof); full scale intelligence quotient, FSIQ; male, 
M. 
Variable (SD) Neurotypicals ASD F(dof) p 
N (M/F) 17 (17/0) 13 (13/0) -- -- 
Age (y) 28.47 (6.55) 30.85 (9.79) F(1) = .634 p = .443 
FSIQ 124.59 (12.71) 114.46 (18.18) F(1) = 3.230 p = .083 
 
 
Fractional Amplitude of low frequency fluctuations (fALFF) 
There were no baseline group differences in fALFF within GM regions (TFCE, pFWE > .05); 
however, there was a main effect of drug. Thus, across both groups, CBD (compared to PLC) 
increased fALFF in the cerebellar vermis VI (TFCE, pFWE = .048, k = 4, centre of gravity in mm 
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(CoG): x = -1, y = -65, z = -6) and in the right fusiform gyrus (TFCE, pFWE = .041, k = 14, CoG: x = 
28.9, y = -48.7, z = -6.86), as depicted in Figure 1. There was no main effect of group, nor a 
drug x group interaction. [insert Figure 1.] 
 
Post-hoc within-group analyses confirmed a significant effect of drug in the ASD group (vermis 
VI: TFCE, pFWE = .045, k = 7, CoG: x = 21.1, y = -55.7, z = -14; fusiform: TFCE, pFWE = .029, k = 19, 
CoG: x = 28.3, y = -51.8, z = -9.58), but not in neurotypicals, as shown in Figure 2. [insert Figure 
2.] 
 
Functional connectivity (FC) 
There were no baseline group differences in vermal or fusiform FC. In the ASD group, CBD 
significantly increased vermal FC with the left (T(11) = 2.57, p = .026) and right caudate (T(11) 
= 2.26, p = .045); and decreased vermal FC with the temporo-occipital part of the left middle 
temporal gyrus (T(11) = -2.81, p = .017), the right anterior supramarginal gyrus (T(11) = -2.73, 
p = .02), the left superior parietal lobe (T(11) = -2.54, p = .027), and the left superior frontal 
gyrus (T(11) = -2.29, p = .043). In contrast, CBD had no significant effect on vermal or fusiform 
FC with any other regions in the neurotypicals; but this between-group difference in 
responsivity was not significant. These findings are summarised in Table 2 and Figure 3. [insert 
Figure 3.] 
 
Table 2 Drug effects on functional connectivity in the autism spectrum disorder (ASD) group. Abbreviations: 
cannabidiol, CBD; left, L; not significant, n.s.; placebo, PLC; right, R. 
Seed region Contrast Target region Statistic 
Drug effect in ASD 
Cannabidiol shifts brain activity and connectivity Pretzsch et al. 
 14 
Vermis VI CBD > PLC 
 
CBD < PLC 
R caudate 
L caudate 
L temporo-occipital middle temporal gyrus  
R anterior supramarginal gyrus 
L superior parietal lobe 
R superior parietal lobe 
L superior frontal gyrus 
T(11) = 2.57,  p = .026 
T(11) = 2.26,  p = .045 
T(11) = -2.81, p = .017 
T(11) = -2.73, p = .020 
T(11) = -2.56, p = .027 
T(11) = -2.54, p = .027 
T(11) = -2.29, p = .043 
Right Fusiform CBD > PLC 
CBD < PLC 
-- 
-- 
n.s. 
n.s. 
 
 
 
 
 
 
 
 
Discussion 
Here we report, for the first time, that CBD ‘shifts’ fALFF and FC in the adult human brain. 
Specifically, we found that CBD significantly increased fALFF in the cerebellar vermis VI and 
the right fusiform gyrus. However, post-hoc within-group testing indicated that this shift was 
most prominent in ASD, and not significant in controls (please note that we did not identify a 
significant group by drug interaction). Moreover, in ASD, but not controls, the shift in fALFF 
in the cerebellum (but not fusiform gyrus) was accompanied by widespread changes in vermal 
FC with several of its subcortical and cortical targets. 
 
Cerebellar vermis 
In the typical brain, the cerebellar vermis and its cerebellar-subcortical-cortical circuitry are 
increasingly understood to subserve a critical role in movement, language, and social 
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processing (D'Mello and Stoodley, 2015). In ASD, however, there have been reports of 
functional anomalies in the cerebellum, which are thought to contribute to the disruption of 
these processes observed in ASD; but the results have been inconsistent.  
 
For example, vermal hypoactivation during simple motor tasks (finger tapping) (Muller et al., 
2001) and during auditory perception (listening to tones) has been observed in adults (Muller 
et al., 1999) with ASD. In children and adolescents with ASD, FC of the vermis with 
sensorimotor regions has been reported to be higher; whereas vermal FC with prefrontal and 
motor regions has been recorded as lower (Khan et al., 2015) compared to neurotypicals. 
Hence, the results of functional imaging studies in ASD may depend on the task under 
investigation. Here we used a non-task design and observed no baseline differences in 
cerebellar fALFF and FC measures (with other regions) in participants with and without ASD. 
Instead, we found that cerebellar activity and connectivity was modifiable, and especially so 
in ASD. Specifically, we found that the CBD-induced increase in vermal fALFF in ASD was 
accompanied by an increase in cerebellar-subcortical (striatal) FC. However, CBD also 
decreased cerebellar-cortical FC. This suggests that, in autistic adults, rather than inducing a 
general and unidirectional shift in FC, CBD appears to ‘tune’ FC in a region- or connection-
specific manner. It was beyond the scope of the present study to examine the cognitive or 
behavioural implications of this response.  
 
Right fusiform gyrus 
In the neurotypical brain, the right fusiform is commonly associated with the visual processing 
of words (McCandliss et al., 2003) and parts of the body (vs objects), e.g. faces (Morris et al., 
2007). In ASD, face processing is overwhelmingly reported to be impaired (Ashwin et al., 2007; 
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Kleinhans et al., 2008); and this is consistent with a wealth of evidence for functional fusiform 
anomalies in this condition. For instance, neuroimaging studies have reported hypoactivation 
(Perlman et al., 2011) and impaired FC (Kleinhans et al., 2008) during face processing. Again, 
using a task-free design we found no baseline differences in the activity of this region; but our 
results indicate that CBD modulates fusiform activity, and the ASD group was particularly 
responsive. Our study design does not speak to whether face processing in ASD would also 
be altered by CBD, but it does indicate that the functional dynamics of this region in ASD differ 
from controls, in that activity can be modulated by CBD. 
 
Although CBD shifted fALFF in both the vermis 6 and right fusiform gyrus, it only altered FC 
between the vermis (and other regions) and not between the fusiform (and other regions) of 
individuals with ASD. The reason for this is not known. One explanation is that the 
connections of the fusiform with other regions are relatively limited, certainly compared to 
the cerebellum. Fusiform FC (with other regions) in ASD specifically may be further restricted 
by the anatomy of the fusiform region in this condition. For example, the grey-white matter 
boundary of the fusiform gyrus has been observed to be disrupted in ASD (Andrews et al., 
2017), as has the integrity of white matter tracts in this location (Barnea-Goraly et al., 2004). 
Abnormalities in white matter connections could restrict the impact of CBD on wider FC from 
this seed. In contrast, previous studies of the vermis indicate that the microstructural integrity 
of white matter connections in this region is intact or even higher in ASD (Noriuchi et al., 2010; 
Ben Bashat et al., 2007); and thus there may be more ‘capacity’ for FC of the cerebellum with 
other regions to change in response to pharmacological challenge in ASD 
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Neurobiological basis of CBD effects on fALFF and FC 
The neurobiological underpinnings of these effects are unclear. However, previous studies 
indicate that CBD can influence excitatory glutamate and inhibitory GABA pathways, which 
play a crucial role in the regulation of LFF and FC (Farrant and Nusser, 2005). 
 
Preclinical studies suggest that CBD has a range of actions which may, for example, converge 
in a modulation of brain excitation and inhibition (Musella et al., 2009; Kaplan et al., 2017; 
Santana et al., 2004). This is important because the balance of excitation and inhibition is 
postulated to help establish and maintain LFF and FC. Inhibitory phasic GABAergic 
interneurons, for instance, are key modulators of temporo-spatial signal integration and 
propagation. Through feed-forward inhibition, these neurons can synchronise large numbers 
of pyramidal cells and thus provide the basis for coordinated firing across distinct brain 
regions (Farrant and Nusser, 2005). Similarly, tonic GABAergic neurons can shape LFF by 
tuning cell conductance and thus controlling the amount and duration of voltage response to 
excitatory input (Farrant and Nusser, 2005). Several targets of CBD in the brain, e.g. TRPV1, 
GPR55, and 5-HT receptors, have been linked to brain glutamate and/or GABA signalling 
(Musella et al., 2009; Kaplan et al., 2017; Santana et al., 2004) and so may impact upon this 
neural activity. For instance, TRPV1-activation through CBD has been reported to increase 
glutamatergic excitation (Musella et al., 2009). In contrast, CBD antagonism on GPR55 has 
been observed to increase the firing of GABAergic interneurons (Kaplan et al., 2017). Finally, 
CBD is an agonist on 5-HT1A and 5-HT2A receptors, which can be found on both excitatory and 
on inhibitory neurons (Santana et al., 2004); thus, CBD action through these receptors may 
both enhance and reduce excitatory and inhibitory transmission. In ASD, however, these 
targets of CBD have been reported to be altered, e.g. (Veenstra-VanderWeele et al., 2012; 
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Kerr et al., 2013). This may partly explain the differential findings in ASD compared to 
neurotypicals observed here.  
 
An alternate explanation for the sensitivity of ASD and not controls to a drug challenge 
targeting glutamate-GABA systems, may be the abnormalities in these systems – and their 
responsivity - in ASD. For instance, there is reduced expression of GABA receptors in the 
fusiform in ASD (Oblak et al., 2011). Similarly, decreased levels both of glutamic acid 
decarboxylase (the enzyme responsible for converting glutamate to GABA) and of inhibitory 
Purkinje cells in the vermis in ASD (Murakami et al., 1989; Yip et al., 2007) suggest inhibition 
deficits in this condition. Thus, our results open the possibility that in ASD, CBD boosts LFF 
(and FC) especially in regions where GABA systems are impaired. This proposed link between 
the glutamate-GABA system and functional circuitry is supported by previous findings of a 
significant correlation between cerebellar excitation-inhibition levels and cerebro-cerebellar 
FC in adolescents and adults with ASD (Hegarty et al., 2018).  
 
 
Limitations 
We acknowledge that our study has important limitations.  
First, our study sample size was modest because: i) we applied strict recruitment criteria (e.g. 
exclusion of candidates with co-morbid psychiatric or medical conditions, which can be 
challenging in ASD); ii) participants were asked to adhere to time-intensive repeated testing 
over several weeks, involving drug administration - this commitment was not always practical; 
and iii) we performed rigorous data quality control, and excluded some datasets. 
Nonetheless, our repeated-measures design mitigated these constraints to some extent by 
Cannabidiol shifts brain activity and connectivity Pretzsch et al. 
 19 
reducing inter-subject variability (each participant had two scans and thus acted as their own 
‘control’) and thus increasing statistical power. In addition, our findings survived rigorous 
statistical thresholding 
 
Second, fALFF analysis is focused on a single frequency range (0.01-0.1 Hz). However, in the 
human brain, a range of frequency bands are thought to interact and to possess hierarchical 
structure. For instance, EEG approaches have shown that delta (1-4 Hz) phase modulates 
theta (4-10 Hz) amplitude, and that theta phase modulates gamma (30-50 Hz) amplitude 
(Lakatos et al., 2005). Future studies are required to investigate the impact of CBD across 
different frequency bands to obtain a more comprehensive view of CBD effects in the 
neurotypical and autistic brain.  
 
Third, in the present study we investigated the impact of acute CBD administration. However, 
the effects of longer periods of treatment with CBD on fALFF and FC (and eventually on 
clinically relevant indices) are difficult to predict and may vary between individuals. 
Therefore, future studies are required to examine the effects of chronic CBD administration 
on brain, and whether the acute response to CBD may help predict the impact of sustained 
treatment.  
 
Fourth, there are two qualifications that need to be considered when interpreting our results. 
These qualifications pertain to most studies of resting state functional connectivity. The first 
pertains to the nature of resting state fMRI: by its nature, this task free paradigm relinquishes 
experimental control over neuronal processing or attentional set. It is therefore possible that 
the differences we have observed reflected group differences in the way that subjects 
Cannabidiol shifts brain activity and connectivity Pretzsch et al. 
 20 
responded to the scanning experience. The second issue is specific to the way in which we 
quantified functional connectivity. By using the correlation coefficient as a measure of 
functional connectivity, we acknowledge that a significant effect on a correlation coefficient 
can be produced either by a change in the linear coupling between two regions, or by a 
difference in noise. In other words, an increase (or decrease) in the correlation coefficient can 
be explained by a decrease (or increase) in noise or random effects due to mental or other 
(e.g., motion) effects. In short, a difference in correlation can be explained either in terms of 
a difference in variance explained in one region by another region – or by a difference in the 
variance not explained (i.e., noise). A more direct way to test for differences in linear coupling 
would have been to use a form of psychophysiological interaction in which the Fisher 
transformed correlation coefficients are replaced by the regression coefficients (obtained by 
regressing the activity of a target region on a source region). We will consider this in future 
work. 
 
 
Conclusions 
In summary, we report the first evidence that CBD ‘shifts’ fALFF and associated FC in the adult 
autistic brain. Thus, in ASD, CBD can alter a crucial property of brain function, and targets key 
regions commonly implicated in the condition. Future studies are required to i) investigate if 
CBD-induced alterations of fALFF and FC in ASD impact on the cognitive processes and 
behaviours these regions modulate; and ii) examine whether brain response to an acute dose 
of CBD may help predict response to sustained treatment in ASD.  
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Figure 1 Drug effects on the fractional amplitude of low frequency fluctuations across the grey matter (cannabidiol > 
placebo). Numbers above the slices indicate location in z-direction (in mm). Scans are oriented in neurological convention, 
where right (R) equals right, and left (L) equals left. P values (P), as indicated by the colorbar, are corrected for multiple 
comparisons (TFCE, FWE). 
Figure 2 Post-hoc test of drug effects on the fractional amplitude of low frequency fluctuations within each region of interest 
(cannabidiol > placebo) in autism spectrum disorder. Top row (A): drug effects within the cerebellar vermis IV; Bottom row 
(B): drug effects within the right fusiform gyrus. Numbers above the slices indicate location in z-direction (in mm). Scans are 
oriented in neurological convention, where right (R) equals right, and left (L) equals left. P values (P), as indicated by the 
colorbar, are corrected for multiple comparisons (TFCE, FWE). 
 
Figure 3 Drug effects on functional connectivity of cerebellar vermis VI in the autism spectrum disorder (ASD) group 
(cannabidiol > placebo). T-values (T) of edges, as indicated by colorbar, are corrected for multiple comparisons at connection- 
and seed-level (p = .05 and pFDR = .05). Abbreviations: autism spectrum disorder, ASD; cannabidiol, CBD; left caudate, L.Caud; 
left superior frontal gyrus, L.SFG; left superior parietal lobe, L.SPL; left middle temporal gyrus (temporo-occipital part), 
L.toMTG; right anterior supramarginal gyrus, R.aSMG; right caudate, R.Caud; right superior parietal lobe, R.SPL; placebo, PLC; 
cerebellar vermis VI, Verm6. 
 
 
 
 
 
 
